Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.
Topline results from two of Merck’s Phase III pediatric trials show the company’s investigational 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
The United States had administered 275,535,207 doses of Covid-19 vaccines in the country as of the morning of May 18 and distributed 346,672,525 doses, the U.S. Centers for Disease Control and Prevention said.
The United States administered Covid-19 vaccinations to around 600,000 children ages 12 to 15 last week after regulators cleared Pfizer’s and BioNTech’s shots for use in that age group, U.S. Centers for Disease Control and Prevention Director Rochelle Walensky said in a media call on May 18.
The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation posted a free digital version of THE CURIOUS EYE at thecuriouseye.org and published a first-run, hardcover book for its member pediatric ophthalmologists.
The World Health Organization urged rich countries on May 14 to reconsider plans to vaccinate children and instead donate Covid-19 shots to the COVAX scheme that shares them with poorer nations.
U.S. states are set to begin using the vaccine from Pfizer Inc. and BioNTech SE to inoculate young adolescents against Covid-19 after advisers to the U.S. Centers for Disease Control and Prevention (CDC) backed the plan in a unanimous vote on May 12.
Advisors to the U.S. Centers for Disease Control and Prevention (CDC) will meet on May 12 to discuss recommendations for the use of Pfizer and partner BioNTech’s Covid-19 vaccine in children aged 12 to 15.
The U.S. Food and Drug Administration approved Chiesi Global Rare Diseases’ Ferriprox (deferiprone) for the treatment of transfusional iron overload caused by sickle cell disease or other anemias in adults and children ages 3 years and older.
BioNTech expects results by September from trials testing the Covid-19 vaccine developed with Pfizer in babies as young as 6 months old, German magazine Spiegel cited the company’s CEO as saying.
